{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T01:10:34Z","timestamp":1790989834126,"version":"4.1.0"},"reference-count":56,"publisher":"American Medical Association (AMA)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"DOI":"10.1001\/jamanetworkopen.2022.1111","type":"journal-article","created":{"date-parts":[[2022,3,18]],"date-time":"2022-03-18T15:32:19Z","timestamp":1647617539000},"page":"e221111","source":"Crossref","is-referenced-by-count":58,"title":["Incidence and Estimated Vaccine Effectiveness Against Hospitalizations for All-Cause Pneumonia Among Older US Adults Who Were Vaccinated and Not Vaccinated With 13-Valent Pneumococcal Conjugate Vaccine"],"prefix":"10.1001","volume":"5","author":[{"given":"Amber","family":"Hsiao","sequence":"first","affiliation":[{"name":"Kaiser Permanente Vaccine Study Center, Oakland, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Hansen","sequence":"additional","affiliation":[{"name":"Kaiser Permanente Vaccine Study Center, Oakland, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julius","family":"Timbol","sequence":"additional","affiliation":[{"name":"Kaiser Permanente Vaccine Study Center, Oakland, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ned","family":"Lewis","sequence":"additional","affiliation":[{"name":"Kaiser Permanente Vaccine Study Center, Oakland, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raul","family":"Isturiz","sequence":"additional","affiliation":[{"name":"Pfizer Vaccine Medicines Development and Scientific Clinical Affairs, Collegeville, Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronika","family":"Alexander-Parrish","sequence":"additional","affiliation":[{"name":"Pfizer Vaccine Medicines Development and Scientific Clinical Affairs, Collegeville, Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John M.","family":"McLaughlin","sequence":"additional","affiliation":[{"name":"Pfizer Vaccine Medicines Development and Scientific Clinical Affairs, Collegeville, Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bradford D.","family":"Gessner","sequence":"additional","affiliation":[{"name":"Pfizer Vaccine Medicines Development and Scientific Clinical Affairs, Collegeville, Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicola P.","family":"Klein","sequence":"additional","affiliation":[{"name":"Kaiser Permanente Vaccine Study Center, Oakland, California"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","published-online":{"date-parts":[[2022,3,18]]},"reference":[{"issue":"37","key":"zoi220062r2","first-page":"822","article-title":"Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine among adults aged =65 years: recommendations of the Advisory Committee on Immunization Practices (ACIP).","volume":"63","author":"Tomczyk","year":"2014","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"3","key":"zoi220062r4","doi-asserted-by":"crossref","DOI":"10.1128\/mBio.00937-20","article-title":"A new pneumococcal capsule type, 10d, is the 100th serotype and has a large cps fragment from an oral streptococcus.","volume":"11","author":"Ganaie","year":"2020","journal-title":"mBio"},{"issue":"5","key":"zoi220062r5","doi-asserted-by":"crossref","DOI":"10.1128\/JCM.00329-21","article-title":"New pneumococcal serotype 15D.","volume":"59","author":"Pimenta","year":"2021","journal-title":"J Clin Micro"},{"issue":"3","key":"zoi220062r6","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1128\/CMR.00018-12","article-title":"Pediatric invasive pneumococcal disease in the United States in the era of pneumococcal conjugate vaccines.","volume":"25","author":"Tan","year":"2012","journal-title":"Clin Microbiol Rev"},{"issue":"6","key":"zoi220062r7","first-page":"144","article-title":"Invasive pneumococcal disease in children 5 years after conjugate vaccine introduction\u2014eight states, 1998-2005.","volume":"57","author":"Centers for Disease Control and Prevention (CDC)","year":"2008","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"36","key":"zoi220062r9","first-page":"893","article-title":"Direct and indirect effects of routine vaccination of children with 7-valent pneumococcal conjugate vaccine on incidence of invasive pneumococcal disease\u2014United States, 1998-2003.","volume":"54","author":"Centers for Disease Control and Prevention (CDC)","year":"2005","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"14","key":"zoi220062r10","doi-asserted-by":"publisher","first-page":"1668","DOI":"10.1001\/jama.295.14.1668","article-title":"Invasive pneumococcal disease among infants before and after introduction of pneumococcal conjugate vaccine.","volume":"295","author":"Poehling","year":"2006","journal-title":"JAMA"},{"issue":"2","key":"zoi220062r11","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1093\/jpids\/piaa035","article-title":"Impact of the 13-valent pneumococcal conjugate vaccine on invasive pneumococcal disease after introduction into routine pediatric use.","volume":"10","author":"Baxter","year":"2021","journal-title":"J Pediatric Infect Dis Soc"},{"issue":"7","key":"zoi220062r12","doi-asserted-by":"publisher","first-page":"1216","DOI":"10.1093\/cid\/ciab375","article-title":"Expanded analysis of 20 pneumococcal serotypes associated with radiographically confirmed community-acquired pneumonia in hospitalized US adults.","volume":"73","author":"Isturiz","year":"2021","journal-title":"Clin Infect Dis"},{"key":"zoi220062r13","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.15585\/mmwr.mm6846a5","article-title":"Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine for adults with immunocompromising conditions: recommendations of the Advisory Committee on Immunization Practices (ACIP).","volume":"68","author":"Matanock","year":"2019","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"12","key":"zoi220062r14","first-page":"1114","article-title":"Polysaccharide conjugate vaccine against pneumococcal pneumonia in adults.","volume":"372","author":"Bonten","year":"2015"},{"issue":"40","key":"zoi220062r15","first-page":"816","article-title":"Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine for adults with immunocompromising conditions: recommendations of the Advisory Committee on Immunization Practices (ACIP).","volume":"61","author":"Centers for Disease Control and Prevention (CDC)","year":"2012","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"10","key":"zoi220062r16","first-page":"1498","article-title":"Effectiveness of 13-valent pneumococcal conjugate vaccine against hospitalization for community-acquired pneumonia in older US Adults: a test-negative design.","volume":"67","author":"McLaughlin","year":"2018","journal-title":"Clin Infect Dis"},{"issue":"46","key":"zoi220062r18","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.15585\/mmwr.mm6846a5","article-title":"Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine among adults aged =65 years: updated recommendations of the Advisory Committee on Immunization Practices.","volume":"68","author":"Matanock","year":"2019","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"3","key":"zoi220062r19","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1080\/14760584.2021.1889376","article-title":"The rationale for use of clinically defined outcomes in assessing the impact of pneumococcal conjugate vaccines against pneumonia.","volume":"20","author":"Gessner","year":"2021","journal-title":"Expert Rev Vaccines"},{"issue":"7","key":"zoi220062r20","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1016\/j.cmi.2020.09.011","article-title":"Effects of 13-valent pneumococcal conjugate vaccination of adults on lower respiratory tract infections and antibiotic use in primary care: secondary analysis of a double-blind randomized placebo-controlled study.","volume":"27","author":"van Werkhoven","year":"2021","journal-title":"Clin Microbiol Infect"},{"issue":"1","key":"zoi220062r21","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1093\/cid\/ciz768","article-title":"Use of chest radiography examination as a probe for pneumococcal conjugate vaccine impact on lower respiratory tract infections in young children.","volume":"71","author":"Ben-Shimol","year":"2020","journal-title":"Clin Infect Dis"},{"issue":"8","key":"zoi220062r22","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1038\/nm1077","article-title":"A role for Streptococcus pneumoniae in virus-associated pneumonia.","volume":"10","author":"Madhi","year":"2004","journal-title":"Nat Med"},{"issue":"10","key":"zoi220062r23","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1097\/00006454-200110000-00008","article-title":"Effect of a conjugate pneumococcal vaccine on the occurrence of respiratory infections and antibiotic use in day-care center attendees.","volume":"20","author":"Dagan","year":"2001","journal-title":"Pediatr Infect Dis J"},{"issue":"22","key":"zoi220062r24","doi-asserted-by":"publisher","first-page":"2935","DOI":"10.1016\/j.vaccine.2019.04.026","article-title":"Effectiveness of the ten-valent pneumococcal Haemophilus influenzae protein D conjugate vaccine (PHiD-CV10) against all respiratory tract infections in children under two years of age.","volume":"37","author":"Karppinen","year":"2019","journal-title":"Vaccine"},{"issue":"5","key":"zoi220062r28","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1017\/S0950268808001489","article-title":"Socioeconomic risk factors for bacteraemic pneumococcal pneumonia in adults.","volume":"137","author":"Flory","year":"2009","journal-title":"Epidemiol Infect"},{"issue":"6","key":"zoi220062r29","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1016\/0895-4356(92)90133-8","article-title":"Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases.","volume":"45","author":"Deyo","year":"1992","journal-title":"J Clin Epidemiol"},{"issue":"14","key":"zoi220062r30","doi-asserted-by":"publisher","first-page":"1488","DOI":"10.1001\/jama.2015.12160","article-title":"Association between hospitalization with community-acquired laboratory-confirmed influenza pneumonia and prior receipt of influenza vaccination.","volume":"314","author":"Grijalva","year":"2015","journal-title":"JAMA"},{"issue":"6 Suppl 2","key":"zoi220062r34","first-page":"66","article-title":"Immunization campaign with 13-valent Pneumococcal Conjugate Vaccine in adults in Liguria Region, Italy: one year post-introduction preliminary results.","volume":"38","author":"Orsi","year":"2014","journal-title":"Epidemiol Prev"},{"issue":"3","key":"zoi220062r35","doi-asserted-by":"publisher","first-page":"699","DOI":"10.4161\/hv.23268","article-title":"Cost-effectiveness of new adult pneumococcal vaccination strategies in Italy.","volume":"9","author":"Boccalini","year":"2013","journal-title":"Hum Vaccin Immunother"},{"issue":"12","key":"zoi220062r36","doi-asserted-by":"publisher","first-page":"2117","DOI":"10.1093\/cid\/ciy993","article-title":"Impact of the 13-valent pneumococcal conjugate vaccine on the incidence of all-cause pneumonia in adults aged =60 years: a population-based, retrospective cohort study.","volume":"68","author":"Kolditz","year":"2019","journal-title":"Clin Infect Dis"},{"issue":"6","key":"zoi220062r37","first-page":"437","article-title":"Clinical trial of an antipneumococcal vaccine in elderly subjects living in institutions.","volume":"33","author":"Gaillat","year":"1985","journal-title":"Revue D'epidemiologie et de Sante Publique"},{"issue":"4","key":"zoi220062r38","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1016\/S0002-9343(97)00149-6","article-title":"Clinical efficacy of pneumococcal vaccine in the elderly: a randomized, single-blind population-based trial.","volume":"103","author":"Koivula","year":"1997","journal-title":"Am J Med"},{"key":"zoi220062r39","doi-asserted-by":"publisher","first-page":"c1004","DOI":"10.1136\/bmj.c1004","article-title":"Efficacy of 23-valent pneumococcal vaccine in preventing pneumonia and improving survival in nursing home residents: double blind, randomised and placebo controlled trial.","volume":"340","author":"Maruyama","year":"2010","journal-title":"BMJ"},{"issue":"9100","key":"zoi220062r40","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1016\/S0140-6736(97)07358-3","article-title":"Randomised trial of 23-valent pneumococcal capsular polysaccharide vaccine in prevention of pneumonia in middle-aged and elderly people.","volume":"351","author":"Ortqvist","year":"1998","journal-title":"Lancet"},{"issue":"2","key":"zoi220062r41","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0171943","article-title":"Effectiveness of 23-valent pneumococcal polysaccharide vaccination in preventing community-acquired pneumonia hospitalization and severe outcomes in the elderly in Spain.","volume":"12","author":"Dom\u00ednguez","year":"2017","journal-title":"PLoS One"},{"issue":"12","key":"zoi220062r42","doi-asserted-by":"publisher","first-page":"2287","DOI":"10.1016\/j.vaccine.2011.01.029","article-title":"Repeat revaccination with 23-valent pneumococcal polysaccharide vaccine among adults aged 55-74 years living in Alaska: no evidence of hyporesponsiveness.","volume":"29","author":"Hammitt","year":"2011","journal-title":"Vaccine"},{"issue":"1","key":"zoi220062r43","doi-asserted-by":"publisher","first-page":"11051","DOI":"10.1038\/s41598-018-29280-2","article-title":"Pneumococcal disease and the effectiveness of the PPV23 vaccine in adults: a two-stage bayesian meta-analysis of observational and RCT reports.","volume":"8","author":"Latifi-Navid","year":"2018","journal-title":"Sci Rep"},{"issue":"4","key":"zoi220062r44","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1086\/649522","article-title":"Safety and antibody response, including antibody persistence for 5 years, after primary vaccination or revaccination with pneumococcal polysaccharide vaccine in middle-aged and older adults.","volume":"201","author":"Musher","year":"2010","journal-title":"J Infect Dis"},{"issue":"7","key":"zoi220062r45","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1093\/cid\/ciu002","article-title":"Effectiveness of the 23-valent pneumococcal polysaccharide vaccine against community-acquired pneumonia in the general population aged = 60 years: 3 years of follow-up in the CAPAMIS study.","volume":"58","author":"Ochoa-Gondar","year":"2014","journal-title":"Clin Infect Dis"},{"issue":"5","key":"zoi220062r46","doi-asserted-by":"publisher","first-page":"1170","DOI":"10.1016\/j.vaccine.2019.11.012","article-title":"Clinical effectiveness of 13-valent and 23-valent pneumococcal vaccination in middle-aged and older adults: The EPIVAC cohort study, 2015-2016.","volume":"38","author":"Vila-Corcoles","year":"2020","journal-title":"Vaccine"},{"issue":"4","key":"zoi220062r47","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1080\/21645515.2017.1409316","article-title":"Effectiveness and practical uses of 23-valent pneumococcal polysaccharide vaccine in healthy and special populations.","volume":"14","author":"Wang","year":"2018","journal-title":"Hum Vaccin Immunother"},{"key":"zoi220062r48","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1016\/j.ijid.2015.05.003","article-title":"Redefining risk categories for pneumococcal disease in adults: critical analysis of the evidence.","volume":"37","author":"Curcio","year":"2015","journal-title":"Int J Infect Dis"},{"issue":"25","key":"zoi220062r51","doi-asserted-by":"publisher","first-page":"3352","DOI":"10.1016\/j.vaccine.2019.04.087","article-title":"Pneumococcal epidemiology among us adults hospitalized for community-acquired pneumonia.","volume":"37","author":"Isturiz","year":"2019","journal-title":"Vaccine"},{"key":"zoi220062r52","article-title":"Prevention of COVID-19 among older adults receiving pneumococcal conjugate vaccine suggests interactions between Streptococcus pneumoniae and SARS-CoV-2 in the respiratory tract.","volume":"jiab128","author":"Lewnard","year":"2021","journal-title":"J Infect Dis"},{"key":"zoi220062r53","doi-asserted-by":"crossref","article-title":"Pneumococcal conjugate vaccine protection against coronavirus-associated pneumonia hospitalization in children living with and without HIV.","author":"Nunes","DOI":"10.1128\/mBio.02347-20"},{"issue":"1","key":"zoi220062r54","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1056\/NEJMc1505366","article-title":"Vaccine against pneumococcal pneumonia in Adults.","volume":"373","author":"Swartz","year":"2015","journal-title":"N Engl J Med"},{"issue":"10","key":"zoi220062r56","doi-asserted-by":"publisher","first-page":"1904","DOI":"10.2105\/AJPH.2009.181313","article-title":"Socioeconomic and racial\/ethnic disparities in the incidence of bacteremic pneumonia among US adults.","volume":"100","author":"Burton","year":"2010","journal-title":"Am J Public Health"},{"key":"zoi220062r31","article-title":"Trends in pneumonia and influenza morbidity and mortality.","author":"American Lung Association, Epidemiology and Statistics Unit","year":"2015"},{"key":"zoi220062r32","doi-asserted-by":"crossref","volume-title":"A public health evaluation of 13-valent pneumococcal conjugate vaccine impact on adult disease outcomes from a randomized clinical trial in the Netherlands","author":"Gessner","DOI":"10.1016\/j.vaccine.2018.05.097"},{"key":"zoi220062r50","author":"Kobayashi"},{"key":"zoi220062r1","unstructured":"Centers for Disease Control and Prevention. Pneumonia. Accessed January 28, 2020. https:\/\/www.cdc.gov\/pneumonia\/index.html"},{"key":"zoi220062r3","unstructured":"Centers for Disease Control and Prevention. Pneumonia can be prevented: vaccines can help. Accessed January 28, 2020. https:\/\/www.cdc.gov\/pneumonia\/prevention.html"},{"key":"zoi220062r8","unstructured":"Centers for Disease Control and Prevention. Surveillance and Reporting. Accessed February 11, 2020. https:\/\/www.cdc.gov\/pneumococcal\/surveillance.html"},{"key":"zoi220062r17","unstructured":"Lessa? F, Spiller? M.? Effectiveness of PCV13 in adults hospitalized with pneumonia using Centers for Medicare & Medicaid Services data, 2014-2017. Presented The Advisory Committee on Immunization Practices Meeting; February 28, 2019; Atlanta, Georgia. Accessed February 1, 2022. https:\/\/stacks.cdc.gov\/view\/cdc\/78092"},{"key":"zoi220062r25","unstructured":"Gordon? N. Similarity of adult Kaiser Permanente members to the adult population in Kaiser Permanente\u2019s Northern California service area: Comparisons based on the 2017\/2018 cycle of the California Health Interview Survey. Published November 8, 2020. Accessed February 1, 2022. https:\/\/divisionofresearch.kaiserpermanente.org\/projects\/memberhealthsurvey\/SiteCollectionDocuments\/compare_kp_ncal_chis2017-18.pdf"},{"key":"zoi220062r26","unstructured":"von Elm? E, Altman? D, Egger? M, Pocock? S, Gotzsche? P, Vandenbroucke? J. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. Accessed February 16, 2022. https:\/\/www.equator-network.org\/reporting-guidelines\/strobe\/"},{"key":"zoi220062r27","unstructured":"Centers for Disease Control and Prevention. Grading of Recommendations Assessment, Development and Evaluation (GRADE) for use of PCV13 among adults =65 years old. Accessed July 22, 2021. https:\/\/www.cdc.gov\/vaccines\/acip\/recs\/grade\/PCV13.html"},{"key":"zoi220062r33","unstructured":"Centers for Disease Control and Prevention, National Center for Health Statistics. Immunization. Accessed February 27, 2020. https:\/\/www.cdc.gov\/nchs\/fastats\/immunize.htm"},{"key":"zoi220062r49","unstructured":"Centers for Disease Control and Prevention. ACIP Recommendations. Accessed December 20, 2021. https:\/\/www.cdc.gov\/vaccines\/acip\/recommendations.html"},{"key":"zoi220062r55","unstructured":"Centers for Disease Control and Prevention. ACIP Presentation Slides: June 23-25, 2021 Meeting. Accessed February 1, 2021. https:\/\/www.cdc.gov\/vaccines\/acip\/meetings\/slides-2021-06.html"}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/articlepdf\/2790262\/hsiao_2022_oi_220062_1647021155.19805.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,18]],"date-time":"2022-03-18T15:32:38Z","timestamp":1647617558000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2790262"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,18]]},"references-count":56,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022,3,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2022.1111","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,3,18]]}}}